middl
east
respiratori
syndrom
coronaviru
merscov
infect
highli
lethal
respiratori
diseas
recent
emerg
middl
east
region
first
report
patient
die
progress
pneumonia
renal
failur
hospit
jeddah
saudi
arabia
june
april
laboratori
confirm
case
human
infect
merscov
includ
least
death
recent
outbreak
korea
infect
busi
man
return
middl
east
introduc
merscov
countri
outbreak
amplifi
superspread
event
hospit
result
laboratoryconfirm
case
fatal
largest
outbreak
outsid
arabian
peninsula
factor
contribut
larg
hospit
outbreak
includ
delay
diagnosi
index
case
overcrowd
emerg
depart
movement
patient
prior
diagnos
suboptim
infect
prevent
control
outbreak
almost
individu
epidemiolog
risk
quarantin
monitor
laboratoryconfirm
case
admit
hospit
isol
soon
diagnos
made
consequ
korean
outbreak
provid
uniqu
opportun
conduct
prospect
studi
merscov
infect
human
infect
highli
virul
respiratori
virus
avian
influenza
sever
acut
respiratori
syndrom
sar
coronaviru
immunopathogenesi
caus
hyperinduct
proinflammatori
cytokin
also
known
hypercytokinemia
cytokin
storm
may
play
import
role
diseas
progress
ultim
mortal
better
understand
immunopathogenesi
merscov
infect
assess
host
immun
respons
viral
kinet
merscov
infect
recent
report
viral
shed
kinet
antibodi
respons
kinet
howev
innat
immun
respons
merscov
infect
role
cytokin
diseas
sever
remain
unclear
report
detail
clinic
cours
cytokin
profil
patient
merscov
infect
also
evalu
associ
cytokin
profil
sever
ill
outbreak
merscov
korea
laboratoryconfirm
case
admit
governmentdesign
hospit
regardless
sever
ill
discharg
hospit
two
consecut
daili
realtim
revers
transcript
rrt
pcr
neg
hour
resolut
clinic
symptom
laboratori
diagnosi
made
guidelin
includ
patient
admit
three
seoul
nation
univers
snu
affili
hospit
snu
hospit
snu
bundang
hospit
snu
borama
medic
center
exclud
patient
admit
day
symptom
onset
patient
studi
report
previous
board
certifi
infecti
diseas
specialist
hospit
prospect
document
clinic
symptom
physic
examin
laboratori
valu
use
standard
case
record
form
patient
transfer
hospit
medic
record
chest
radiograph
patient
hospit
also
review
serum
sampl
collect
serial
interv
store
patient
categor
sever
mild
group
depend
upon
oxygen
supplement
requir
sever
group
requir
oxygen
supplement
maintain
arteri
satur
cytokin
level
serum
assess
enzymelink
immunosorb
assay
elisa
use
verikin
elisa
kit
pbl
assay
scienc
piscataway
nj
usa
interferon
interferon
human
duoset
kit
r
system
minneapoli
mn
usa
interferon
interleukin
interleukin
interleukin
interleukin
interleukin
interleukin
cxc
motif
chemokin
tumor
necrosi
factor
transform
growth
factor
assay
rang
elisa
kit
shown
supplementari
tabl
mannwhitney
u
test
use
analyz
differ
two
group
spearman
rank
correl
use
determin
correl
variabl
statist
analys
perform
ibm
spss
statist
softwar
spss
inc
chicago
il
usa
signific
test
twosid
institut
review
board
seoul
nation
univers
hospit
review
studi
protocol
provid
studi
approv
board
waiv
requir
written
consent
irb
registr
number
total
patient
includ
studi
demograph
clinic
characterist
patient
shown
tabl
median
incub
period
day
rang
day
median
interv
symptom
onset
isol
unit
day
rang
day
clinic
symptom
first
week
ill
fever
cough
malais
anorexia
chill
diarrhea
dyspnea
nausea
sore
throat
chang
frequenc
symptom
time
ill
onset
partli
shown
supplementari
fig
median
time
defervesc
day
fig
dyspnea
develop
end
first
week
becam
appar
second
week
nine
patient
patient
need
oxygen
supplement
tabl
median
time
symptom
onset
oxygen
supplement
day
ill
rang
day
ill
median
time
hospit
discharg
day
ill
rang
day
ill
laboratori
chang
shown
fig
supplementari
tabl
sever
group
higher
neutrophil
count
week
mild
group
vs
p
fig
overal
lymphopenia
mark
lymphocyt
count
less
midfirst
week
midthird
week
fig
platelet
count
rare
develop
sever
mild
group
clinic
signific
abnorm
coagul
panel
prothrombin
time
activ
partial
thromboplastin
time
fig
hypoalbuminemia
develop
second
week
especi
sever
group
fig
median
lowest
level
serum
albumin
significantli
low
sever
group
gdl
sever
group
gdl
mild
group
p
two
patient
patient
b
e
elev
serum
creatinin
level
patient
b
underli
diseas
diabet
hypertens
chronic
renal
diseas
receiv
nephrotox
drug
patient
e
metastat
bladder
cancer
renal
failur
due
metastat
urinari
obstruct
detect
experi
set
serum
patient
cours
diseas
detect
patient
show
signific
relationship
clinic
cours
sever
ill
serum
level
increas
cours
diseas
sever
case
pegyl
inject
six
among
nine
sever
case
appar
respons
mild
group
except
one
patient
receiv
inject
fig
compar
peak
viral
load
merscov
sputum
serum
level
cytokin
chemokin
first
week
ill
signific
correl
observ
p
fig
serum
level
increas
usual
peak
day
fig
peak
higher
delay
one
week
sever
group
mild
group
fig
second
week
ill
serum
level
significantli
higher
sever
group
median
pgml
rang
mild
group
median
pgml
rang
p
serum
level
also
significantli
higher
sever
group
median
pgml
rang
mild
group
median
pgml
rang
p
supplementari
fig
studi
present
clinic
progress
cytokin
profil
merscov
infect
korean
outbreak
merscov
almost
close
contact
activ
monitor
soon
pcr
test
merscov
posit
admit
hospit
design
govern
therefor
could
identifi
exact
date
exposur
symptom
onset
abl
conduct
prospect
studi
clinic
manifest
merscov
infect
rang
asymptomat
infect
fatal
pneumonia
studi
common
present
symptom
fever
chill
cough
upper
respiratori
symptom
rhinorrhea
sore
throat
rare
previou
studi
report
pneumonia
progress
rapidli
median
time
need
mechan
ventil
day
rang
day
studi
howev
patient
pneumonia
week
symptom
sever
feel
need
stay
home
walk
pneumonia
dyspnea
requir
oxygen
supplement
sudden
progress
pneumonia
usual
develop
second
week
similar
sar
median
time
symptom
onset
ventil
support
day
clinic
progress
initi
mild
symptom
follow
sudden
clinic
deterior
patient
merscov
infect
may
present
emerg
room
er
therefor
er
depart
prepar
earli
detect
isol
possibl
mer
case
appropri
infect
prevent
control
method
common
laboratori
abnorm
anemia
lymphopenia
thrombocytopenia
elev
alanin
aminotransferas
level
laboratori
chang
mild
first
week
sever
even
patient
progress
pneumonia
prolong
activ
partialprothrombin
time
rare
develop
even
pneumonia
progress
respiratori
failur
low
albumin
level
predictor
sever
pneumonia
merscov
infect
also
note
develop
progress
pneumonia
associ
decreas
serum
albumin
level
acut
renal
impair
initi
report
characterist
featur
mer
subsequ
studi
saudi
arabia
report
almost
half
patient
mer
requir
renal
replac
therapi
studi
exclud
patient
e
metastat
bladder
cancer
urinari
obstruct
one
patient
show
acut
kidney
injuri
strike
differ
incid
renal
impair
like
due
low
preval
underli
condit
chronic
renal
diseas
diabet
hypertens
popul
evas
immun
system
human
critic
merscov
surviv
replic
host
merscov
known
inhibit
recognit
delay
ifn
induct
sequest
ifn
stimul
gene
product
peak
viral
titer
achiev
fatal
mer
case
patient
could
induc
express
key
receptor
retino
acidinduc
gene
melanoma
differentiationassoci
protein
respons
merscov
infect
result
decreas
express
ifn
regulatori
factor
lead
decreas
express
studi
serum
level
sever
mer
group
frequent
high
mild
group
even
could
demonstr
statist
signific
contrari
appar
respons
mild
group
fig
level
also
correl
log
valu
maxim
rna
copi
fig
taken
togeth
seem
surg
clinic
cours
mer
patient
sever
diseas
high
viral
load
patient
mild
diseas
absenc
surg
sever
case
diseas
relat
wors
outcom
previou
studi
could
conclud
associ
outcom
serum
level
due
limit
number
fatal
case
moreov
possibl
level
serum
mere
reflect
level
exogen
inject
pegyl
studi
therefor
result
level
serum
read
cautious
one
import
proinflammatori
cytokin
divers
biolog
activ
mani
clinic
situat
includ
respiratori
viral
infect
chang
serum
level
merscov
infect
clearli
document
yet
increas
serum
earli
phase
respiratori
viral
infect
reveal
human
case
sever
season
influenza
pandem
influenza
pneumonia
fatal
avian
influenza
case
sarscov
infect
elev
level
subsequ
peak
viral
replic
observ
pneumonia
case
includ
induc
merscovinfect
human
monocytederiv
macrophag
significantli
upregul
lung
lesion
merscovinfect
anim
studi
overal
level
significantli
higher
sever
mer
group
mild
group
howev
level
sever
mer
group
higher
week
symptom
onset
statist
signific
analyz
tempor
trend
supplementari
fig
also
known
protein
chemoattract
express
inflam
bronchial
epitheli
cell
respons
seem
play
import
role
sever
respiratori
viral
ill
uncontrol
durabl
secret
first
week
follow
onset
symptom
associ
poor
outcom
sever
mer
case
high
serum
level
also
document
sever
respiratori
viral
ill
sever
avian
influenza
avian
influenza
sever
season
influenza
sar
studi
level
serum
significantli
higher
sever
mer
group
mild
group
second
third
week
ill
supplementari
fig
clinic
cours
serum
level
show
peak
around
second
week
symptom
onset
sever
group
fig
dynam
proinflammatori
cytokin
respons
show
good
tempor
correl
chest
infiltr
show
peak
second
week
symptom
onset
sever
mer
case
therefor
studi
suggest
elev
level
serum
may
associ
sever
pneumonia
mer
studi
limit
small
number
patient
includ
five
patient
concurr
infecti
diseas
might
affect
clinic
cours
laboratori
featur
merscov
infect
nine
patient
receiv
pegyl
could
affect
serum
level
cytokin
profil
cytokin
feedback
cascad
howev
group
profil
similar
regardless
administr
pegyl
also
subset
analysi
includ
patient
receiv
interferon
therapi
show
similar
trend
supplementari
fig
spite
limit
studi
strength
collect
clinic
data
serum
sampl
serial
prospect
manner
divers
cytokin
chemokin
level
measur
newli
emerg
diseas
conclus
patient
merscov
infect
present
walk
pneumonia
first
week
ill
may
deterior
suddenli
around
day
ill
serum
level
significantli
elev
sever
case
second
week
ill
